I have filed a provisional patent application with the US patent office for a blood serum cancer test.
Brief details are this test is intended as a whole body cancer screen, thought capable of detecting stage 0-1 cancers with 90% accuracy, and stage 1-2 cancers with over 99% accuracy, according to preliminary data.
This blood test is designed to be a binary test that does not reveal tissue of origin, but has many applications in the diagnosis and treatment of cancer. A key feature of this test, is that it is almost impossible to have a false positive result, so can also be used as a companion test with diagnostic scans, to confirm a cancer without the need for a tissue biopsy.
A proof of concept study is planned at the National Physical Laboratory (NPL)London, with the expectation that the resultant data will confirm the basis of a new blood test able to reveal if a patient has cancer or is cancer free, in a space where there is no such test.
I am particularly pleased to have entered into a collaboration with the NPL which is the UK's National Measurement Institute, and is a world-leading centre of excellence in developing and applying the most accurate measurement standards, science and technology available.
This proposed test is an evolution of a SMART awarded study.
June 6th 2018